TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Explore how the ratio of pd-1+ treg to ctl and the presence of tertiary lymphoid structures can influence treatment outcomes ...

MSD partners LaNova Medicines on a PD-1 and VEGF targeting candidate for cancer, a potential replacement for its top-seller Keytruda.

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, primarily due to its dense, desmoplastic and immunosuppressive tumor microenvironment (TME) that hinders the efficacy of ...

Novel analogues of the P2 receptor antagonist pyridoxal-5‘-phosphate 6-azophenyl-2‘,5‘-disulfonate (2) were synthesized and studied as antagonists in functional assays at recombinant rat P2X1, P2X2, ...

The conversion of acetylcholine binding into ion conduction across the membrane is becoming more clearly understood in terms of the structure of the receptor and its transitions. A high-resolution ...

During animal development, cells divide and arrange themselves in a coordinated way, eventually forming the embryo. The cells ...

Study links impulsive, antisocial psychopathy traits to specific brain changes, offering new insight into diagnosis and potential rehabilitation strategies.

Investigating how mutations in tumors alter DNA’s 3D structure—and subsequently, regulatory sequences called enhancers—can offer new treatment opportunities.